小剂量利妥昔单抗治疗难治性特发性血小板减少性紫癜  

Low dose rituximab therapy for patients with refractory idiopathic thrombocytopenic purpura

作　　者：金洁萍[1] 李斌[1] 张宁[1] 

机构地区：[1]辽宁医学院附属第一医院血液科,锦州121001

出　　处：《北京医学》2011年第10期803-805,共3页Beijing Medical Journal

摘　　要：目的探讨小剂量利妥昔单抗治疗难治性特发性血小板减少性紫癜（ITP）临床效果、安全性及经济效果。方法选择我院住院17例难治性ITP患者，采用利妥昔单抗（100mg，每周1次，连用4周），监测治疗前后血常规、血清免疫球蛋白定量和血小板相关抗体。结果治疗后血小板计数为（76．4±58．6）×10^9／L，治疗有效率为64．7％；随访6～39个月，复发率36.4％，无严重不良反应；治疗成本明显低于标准剂量的利妥昔单抗。结论小剂量的利妥昔单抗是治疗难治件ITP安伞、有效药物，价格适中.Objective To explore the clinical efficacy, safety and economic effectiveness in patients with refractory idiopathic thromboeytopenic purpura （ITP） treated with low dose rituximab. Methods Seventeen patients with refractory ITP were treated with low dose rituximab （100 mg per week for 4 weeks） in our hospital. Whole blood cell count, quantitative analysis of immune globulins, platelet antibodies were detected before and after rituximab therapy. Results The clinical efficacy rate of this treatment regimen was 64.7%, and the recurrence rate was 36.4%. There were no severe adverse effects during rituximab therapy. The therapy cost was significantly lower than regular rituximab treatment regimen. Conclusion Low dose rituximab therapy is effective and safefor patients with ITP, and the cost is lower than regular dose regimen.

关 键 词：特发性血小板减少性紫癜 利妥昔单抗 治疗 

分 类 号：R554.6[医药卫生—血液循环系统疾病]